A variety of new crown oral drugs, anticancer drugs and rare medicines, review through medical insurance forms

Economic Observation Network reporter Qu Yixian on September 17, the State Medical Insurance Administration officially announced the "List of Application Drugs, Catalog of Catalog of National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (hereinafter referred to as" List "), a total of 343 species) The medicines are officially reviewed in form, and a number of new crown oral drugs, domestic innovative biopharmaceuticals and rare diseases are listed.

Specifically, in terms of the new crown drugs, the first domestic new crown oral medicine Azf's fixed tablet, Pfizer's new crown oral Yaomaltova/Litonovir tablet packaging is in the "List".

In terms of innovative biopharmaceuticals, Yaoming Junuo (02126.HK) CAR-T cell therapy Rock Olun Sai, Corning Jerry (09966.HK) PD-L1 Ervolimab, Fuhong Hanlin (02696. HK )'s PD-1 inhibitor Suduley Mipoly, Baiji Shenzhou (06160.HK/688235.SH) was introduced by Steccoxima, Hansen Pharmaceutical (03692.HK )'s first biological new medicine Inaili Pearl Mipida, Kangfang Biological (09926.HK) PD-1/CTLA-4 dual anti-Kardini Mippitum all passed formal review.

In the field of rare diseases, nearly 30 adaptive symptoms include the country's "First Batch of Rare Disease Catalogs". Enzyme β, the injecting of goshylidinase for the treatment of Gobbin, and the treatment of adhesive polysaccharide accumulation I type. The initial pricing is "sky -high", and the annual treatment costs are almost all million yuan.

On September 6, the National Medical Insurance Administration released the "List of Drugs that National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogs were adjusted" in 2022, including the 198 category of category of cathabilal and Chinese patent medicine and Ada Mu Mipida. Wait for the 145 categories of western medicine and Chinese medicine, and please supervise the qualifications, relevant information and preliminary form review results of publicized medicines from all walks of life. The publicity period is one week.

Compared with the 344 drugs in the list of drugs that passed the preliminary form of review, the official "List" reduced one type of western medicine -metamow ginseng vaginal expansion thrombosis.

However, through formal review, it does not mean that it can really enter the negotiation link.

In accordance with the "Interim Measures for the Management of Basic Medical Insurance Drugs" and "Temporary State Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog" (hereinafter referred to as the "Work Plan"), medical insurance catalog adjustment is divided into enterprise declaration, formal review , Expert review, negotiation bidding, etc., formal review is only one of them.

Through form review, the drug is eligible to enter the next expert review session. Experts can enter the negotiation bidding session.

When the preliminary examination list was released before, the National Medical Insurance Bureau stated that some expensive drugs this year passed preliminary examinations. It only stated that the drug meets the application conditions and has obtained the qualification to enter the next link. Whether this type of medicine can eventually enter the national medical insurance drug catalog also needs to be strictly evaluated in many ways to include economics. The exclusive drugs that pass the review must be negotiated and the non -exclusive drugs must be bidded. Essence

In the context of the normalization of the epidemic prevention and control, from the first implementation of the independent application system of the medical insurance drug directory enterprise in 2020, the State Medical Insurance Bureau will "include the" New Coronatte Pneumonic Pneumonia Diagnosis and Treatment Plan "(hereinafter referred to as the" diagnosis and treatment plan ")) "Pharmaceutical" as one of the application conditions. A number of new crown therapy medication has been included in the medical insurance catalog.

The ninth edition of this year's "Diagnosis and Treatment Plan" has been included in a group of drugs that have just been listed in China. During the application process, some medicines conducted independent declarations and passed preliminary examinations. Some drugs did not declare. For drugs that have been declared and passed through formal review, the National Medical Insurance Administration stated that it will carry out follow -up work in accordance with procedures and strive to be officially included in the medical insurance directory at a reasonable price.

- END -